source
- Regeneron doubles down on CytomX after other pharmas walked awayAfter losing a couple of pharma alliances in recent quarters, CytomX Therapeutics is getting a major lift from a key collaborator. Regeneron is doubling down on its partnership with the Bay Area bi…Endpoints · 1mo ago↗ source
- Mineralys makes money moves before looming hypertension approvalMineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug called lorundrostat. It came with a tiny $1 million upfront fee to the medicine's originator,…Endpoints · 1mo ago↗ source
- STAT+: What the pope’s encyclical on AI means for Catholic hospitals, and all of health careIn this edition of STAT's AI Prognosis: Brittany Trang analyzes the pope's encyclical on artificial intelligence for takeaways relevant for health care.